Another HIF-1α inhibitor, Bortezomib inhibits p300-HIF-1α binding at nanomolar concentrations (0.6–30 nM), almost equivalent to Compound 12 to repress HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/mTOR and MAPK pathways in prostate cancer cells [23]. Here, EP300 is linked to prostate carcinoma.